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Answering the CDC’s Call for Universal HIV Testing: Assessing the Impact on a Tertiary Care Referral Center via a Blinded Seroprevalence Study
Margaret Hoffman-Terry, MD, K. Nadeem Ahmed, MD, Joseph Yozviak, DO, Sherrine Eid, MPH, Kimberly Pacella, Timothy Friel, MD, Luther V. Rhodes, III, MD. Lehigh Valley Hospital and Health Network, Allentown, PA

ABSTRACT:
Objective: To obtain an accurate picture of the HIV epidemic in the inpatient and outpatient population served by a
large tertiary care referral center by conducting a blinded seroprevalence study.
Methods: 601 outpatients (OP) and 399 inpatients (IP) were included. All leftover blood samples in the central
laboratory were de-identified and then consecutively tested for HIV via ELISA with confirmatory Western blot and HCV
via Abbott’s Microparticle Enzyme ImmunoAssay with RIBA performed for those not meeting the CDC’s recommended
signal to cut-off ratio of 9.9 for true antibody positivity. Sampling was stratified to be representative of the age groups
served by this 3 site, 986 bed hospital system. OPs were oversampled in an attempt to more accurately represent the
epidemic in the community served by the hospital system.
Results: Of the 9 who were confirmed HIV positive, 7 ( 78%) were IP compared to 2 (22%) OP (Fisher’s exact test p=.024).
HIV positive pts. were 5.34 times as likely to be IP as OP (OR 5.34, CI [1.11,25.78]). 5 (56%) were male compared to 4
(44%) female (Fisher’s exact test p>.05). 8/9 cases fell in the 25-54 range, with the largest subgroup being those pts.
between 45-54 years of age (4/9). 6/9 were from the urban area immediately surrounding the hospital sites, 1 from
the suburbs, 1 from a rural community, and 1 from a distant city served by the network. Only 3 HCV co-infected cases
were found-all IP, from an urban area, and between the ages of 47-50. One case of HIV was confirmed in the 65-80 year
range-beyond the age recommended for testing by the CDC.
Conclusions: The IP positivity rate of 1.75% is well above the 1% rate felt necessary for cost effective testing of a
population and supports the current CDC recommendation to offer testing to all patients as they access healthcare in
an attempt to identify new cases. The OP rate of 0.33% was surprisingly low and points to the need to develop novel
strategies for identifying HIV cases among those not regularly accessing the healthcare system.
INTRODUCTION:
HIV is typically symptomatic for only a few weeks after acute infection and then silent for 10-12 years until the
immune system is shattered and Acquired Immunodeficiency Syndrome (AIDS) ensues. The Center for Disease Control
currently indicates that there are more than 1 million Americans living with HIV infection. More strikingly, the CDC
estimates that approximately one quarter of these individuals have never been tested for HIV and are therefore
unaware of their status and that this population causes 54 to 70% of new infections1. In years past the CDC had
recommended targeted testing of high-risk populations, a policy under which we have continued to see approximately
50,000 new infections annually in the US, with many patients presenting late in the course of their disease. Since 2006
the CDC has recommended Universal Testing. Under this policy, HIV screening is recommended for patients ages 18-64
in all health-care settings after the patient is notified that testing will be performed unless the patient declines (opt-out
screening). Those at high risk for HIV infection should be screened for HIV at least annually. Separate written consent
and prevention counseling should not be required2.
Because of shared modes of transmission, 25-90% of HIV patients, depending on the subpopulation being studied,
are co-infected with chronic Hepatitis C 3,4. The metamorphosis of HIV from a rapidly fatal to a chronically manageable
disease means that persons with HIV now go on to die from illnesses other than traditional opportunistic infections.
The diseases they most commonly die from now across the US are cancers followed by end stage liver disease related to
hepatitis C5, and the Lehigh Valley has followed this trend. From 2000-2005, 58% of deaths in our HIV clinic occurred in
the 35% of our HIV patients who were co-infected, with 29.5% of deaths the result of end stage liver disease secondary
to HCV6. To evaluate the extent of one epidemic without evaluating the other seemed imprudent since the two are so
closely intertwined.
The implications of Universal HIV Testing are manifold. Who will fund this testing? How do we change state laws
to comply with these recommendations? Who will care for these patients this age of healthcare cost constraints with
fewer HIV providers available every year? We sought to examine the following question: How many HIV cases will be
identified in this manner and how many will be coinfected with HCV?
OBJECTIVE:
To establish a precise seroprevalence of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) in the
community serviced by Lehigh Valley Hospital and Health Network (LVHHN) including the hospital and the Lehigh
Valley Physicians’ Practice which serves a primarily uninsured/ underinsured population. This provided us with 2 key
pieces of information: the actual number of persons infected with HIV alone and the degree of co-infection with both
viruses. Furthermore, we analyzed differences in age, gender, and zip code (as surrogate marker of residence) in an
effort to understand these intertwined epidemics.

METHODS:
The strategy was to indiscriminately screen 1000 patients between the ages of 18 and 80 who have leftover blood
after having labs drawn in the LVHHN. Based on a 99% confidence interval with a 5% margin for error, an adequate
sample size is 1000 subjects. All red top tubes drawn for basic metabolic profiles were sequentially allocated beginning
at 0600 on February 6, 2008 until 400 inpatients (220 females and 180 males) and 600 outpatients (368 females and
232 males) including those seen in the emergency department were sampled. The sample were stratified into age and
sex groups based on admission statistics of the previous year (Table 1). Proportions of admissions of each age group
were determined based on inpatient or outpatient status. Inpatient was defined as anyone in a bed at 12 AM midnight
at all LVH sites, including all medical, surgical, psychiatry, hospice and transitional skilled units, including observation
admissions. Outpatient visits were determined to be emergency department visits, clinics, same day surgery, cancer
patients receiving services at the Cancer Center’s Multi-purpose area, and home hospice.
The age groups for each sex were: Group I –ages 18-24, Group II –ages 25-34, Group III –ages 35-44, Group IV –ages
45-54, Group V –ages 55-64 Group VI –ages 65-80. Specimens were chosen in an anonymous and unlinked fashion to
protect the confidentiality of the patients. Neither the researchers nor the patients are able to track the results to the
sample source. Since each specimen is no longer traceable or linked to its source, the researchers in this project were
not obligated to notify the patients of the results as that would be impossible after each specimen was de-identified.
The protocol was reviewed by our hospital ethicist and approved by the Institutional Review Board and HIPAA
compliance officer.
The LVHHN laboratory tested all blood received during the time period indicated only after a medical technician had
removed all identifiers. As each specimen was received and frozen, a master list of the last four digits of the medical
record number was recorded to avoid duplication until sampling was complete. Each specimen was then assigned a
unique consecutive case number starting at 100 through 1100, with this number entered independently in a second
database. In this second database with the newly assigned case number, demographic information including age, sex,
Zip code, and site of collection (Inpatient, ER, and Outpatient) was recorded. The first database containing the last 4
digits of the medical record number was deliberately destroyed in the presence of our hospital’s compliance officer
upon completion of sampling and prior to any serologic testing to assure blinding and prevent association of any kind
between medical record number and sample result.
The frozen blood samples were thawed and tested consecutively for antibodies to HIV and HCV using the Enzyme
Linked Immunosorbent Assay (ELISA). A confirmatory Western blot was performed for all positive HIV ELISAs. HCV
testing was done using Abbott’s Microparticle Enzyme ImmunoAssay with RIBA performed for those not meeting the
CDC’s recommended signal to cut-off ratio of 9.9 for true antibody positivity. The specimen requirements of ELISA are
minimal so there was no need for additional blood draws. The results of the diagnostic test (ELISA) were then recorded
in the second database devoid of medical record numbers. Many HIV and HCV studies, including a recent Philadelphia
study of HIV and a Houston study of HCV, had been successfully conducted in this blinded manner 7,8.
Variables: To compare the demographic and epidemiologic data between populations in the LVHHN versus other
urban/rural areas regionally and nationwide, the following variables were identified for all samples tested:
• Age
• Gender
• Zip code of residence
• Source of blood sample-outpatient, ER, inpatient
• Infection with HIV and /or HCV
Analytic Methodology: The stated indicators were analyzed by the LVHHN Health Studies Department using
univariate and multivariate analyses in SPSS 15.0 statistical software. T test and Pearson’s Chi-square analyses were
conducted on the provided data examining differences in infection rates by region, age, and gender. In addition to this,
associations were examined using Pearson’s correlation. Descriptive statistics on demographics and overall results
using Poisson lower and upper bounds were reported. The Poisson limits identify plausible ranges and reflect the
95% confidence intervals. Seroprevalence was determined by the equation; P=x/n, where x is the number of positive
samples and n is the overall sample.
RESULTS:
1000 patients were included in this HIV/HCV seroprevalence study. Nine were confirmed HIV positive and twentyeight cases were confirmed HCV positive with three confirmed co-infected with HCV and HIV. The outpatient setting
was over sampled in an attempt to capture as many individuals and potential cases not currently in the system.
Of those were HIV positive, nearly 78% were inpatients compared to 22% outpatient (Fisher’s Exact Test p=.024). HIV
positive patients were 5.34 times as likely to be inpatients than outpatients (OR 5.34, CI [1.11,25.78]). The distribution
of men and women was not statistically significant. Nearly 56% were men compared with 44% HIV positive women
(Fisher’s exact test p>.05).

RESULTS (cont.):
The overwhelming majority of HIV positive cases were between the ages of 25-54, with the largest subgroup being those
patients between 45-54 years of age; 11.1% of HIV positive cases were between the ages of 65-80. 6/9 were from the urban
area immediately surrounding the hospital sites, 1 from the suburbs, 1 from a rural community, and 1 from a distant city
served by the network. Only 3 HCV co-infected cases were found-all IP, from an urban area, and between the ages of 4750.One case of HIV was confirmed in the 65-80 year range-beyond the age recommended for testing by the CDC.
Men were 2.2 times more likely to be HCV positive than women (OR 2.229 CI [1.033,4.810]). There was no difference in the
distribution of HCV-infected patients with regards to being inpatient or outpatient (Pearson’s χ2 p>.05). HCV cases tended to
be more scattered between urban, suburban and rural areas with HIV cases concentrated in urban areas.
Table 1: LVHHN Hospital Discharge Data Dec.
2005 – Nov. 2006
LVHHN Hospital Discharge Data
Inpatient
Age Group
Male
Group I 18-24
9
Group II 25-34
13
Group III 35-44
23
Group IV 45-54
37
Group V 55-64
39
Group VI 65-80
58
Total
180
Outpatient
Age Group
Male
Group I 18-24
25
Group II 25-34
32
Group III 35-44
42
Group IV 45-54
48
Group V 55-64
40
Group VI 65-80
45
Total
232

Table 2. HIV Breakdown by Age Group
Age Group

Female
18
32
34
40
39
57
220
Female
35
48
69
83
65
68
368

HIV
Positive
Total

Total

18-24

25-34

35-44

45-54

55-64

65-80

0%
(0)

33.3%
(3)

11.1%
(1)

44.4%
(4)

0%
(0)

11.1%
(1)

100%
(28)

8.5%
(85)

12.5%
(125)

16.8%
(168)

20.8%
(208)

18.3%
(183)

23.1%
(231)

100%
(1000)

Table 3. HCV Breakdown by Age Group
Age Group

Total

18-24

25-34

35-44

45-54

55-64

65-80

HCV
Positive

3.6%
(1)

3.6%
(1)

21.4%
(6)

60.7%
(17)

7.1%
(2)

3.6%
(1)

100%
(28)

Total

8.5%
(85)

12.5%
(125)

16.8%
(168)

20.8%
(208)

18.3%
(183)

23.1%
(231)

100%
(1000)

CONCLUSION:
Establishing the seroprevalence of HIV and HCV by ensuring anonymity and unlinked data serves as a model in assessing overall
disease burdens in the Lehigh Valley, as it has in other communities and large cities. Given the growing disease burden of these
synergistic infections, it is of paramount importance to accurately determine seroprevalence and identify cases early in their
disease course when treatment will be most efficacious. The IP positivity rate of 1.75% is well above the 1% rate felt necessary for
cost effective testing of a population and supports the current CDC recommendation to offer testing to all patients as they access
healthcare in an attempt to identify new cases. The fact that 7/9 HIV positives were found in inpatients in this day and age when
our usual inpatient census is 1 and most patients live for decades only being cared for in the outpatient arena was surprising. Eight
of nine patients would have been diagnosed under Universal Testing guidelines, though one of our 9 cases was found in a patient
over 64 years of age who would have thus fallen outside the CDCs recommended age window for HIV testing. The OP rate of
0.33% was surprisingly low and points to the need to develop novel strategies for identifying HIV cases among those not regularly
accessing the healthcare system.
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